MK-677 (Ibutamoren)
Swallow it daily and your growth hormone rises, along with puffiness, hunger, and blood sugar.
- What it is
- A pill you swallow that pushes your body to make more growth hormone
- Is it FDA-approved?
- No. Merck tested it, then dropped it. Sold 'for research only'
- How strong is the proof?
- More human data than most peptides here, but it was never approved
- How you take it
- By mouth, often about 25 mg a day. Pill only, never a shot
- Typical result
- IGF-1 (a growth signal) goes up 40-80%. Water weight and hunger go up too
- Biggest catch
- Puffiness, higher blood sugar, and a long-term cancer worry
Any word with a dotted underline is a science word — tap it for a plain-English meaning.
In plain words.
MK-677, also called Ibutamoren, is a pill. It is not really a . It is a small lab-made chemical you swallow.
Your body makes growth hormone in bursts. MK-677 copies a gut hormone called ghrelin and tells your body to make more growth hormone around the clock. That raises a growth signal called .
A big drug company, Merck, tested it years ago and then stopped. So there is no approved version. It is sold "for research only." Note: it is a pill, not a shot. Anyone selling "injectable MK-677" is selling a fake.
What people use it for.
People use it to chase the things growth hormone is linked to: more muscle, better sleep, and quicker recovery.
Lifters like it because it is a pill, not a daily shot. Older people use it hoping to hold onto muscle.
It is banned in tested sports (WADA-banned), so do not use it if you compete.
Does it actually work?
In one sense, yes. It clearly raises your growth signal, , by about 40 to 80 percent. There were several real human trials, which is more than most peptides here have.
But here is the honest part. Merck ran a trial in older people for hip-fracture recovery. People got some function back, but there was a worrying signal of more heart failure. So Merck walked away. A company dropping its own drug is itself a data point.
So it "works" at raising hormones. Whether that is safe long-term is the open question.
what you’ve probably heard.
The claims floating around online, and how true they actually are.
“MK-677 can make you taller, even as a grown adult.”
mythIt raises your growth signal, , but that is not the same as adding height once you are done growing. There is no data showing it makes a grown adult taller.
“It builds muscle almost like a mild steroid.”
overblownIt does push up 40 to 80 percent, but raising that growth signal is not the same as building real muscle. A lot of the early 'gains' are just 3 to 7 pounds of water.
“It's basically natural and safe, it just nudges your own growth hormone.”
noMerck tested it in older adults, saw a heart-failure signal, and dropped its own drug. It also pushes blood sugar up and keeps high around the clock, which carries a long-term cancer worry.
“Getting puffy and gaining weight fast means it's working.”
half trueThe water weight is real and shows up in the first couple weeks. But that bloat and the big jump in hunger are side effects, not muscle.
How you take it.
You take it by mouth. The common amount people use is about 25 mg a day. It is a pill or a liquid you swallow, never a shot.
Most of the action builds over weeks. Water weight shows up in the first 2 weeks. The growth signal peaks around weeks 8 to 12.
There is no slow ramp-up needed like with the weight-loss shots. But watch your body closely, which we cover next.
What to watch out for.
The common stuff
Most people get puffy and gain 3 to 7 pounds of water weight in the first couple weeks. Hunger goes way up. Some feel tired.
The serious stuff
- Your blood sugar can climb. This can push you toward diabetes. Stop if your fasting blood sugar goes over 100 or your A1c (a blood sugar test) is rising.
- It can cause swelling in your legs and feet. Stop if that happens.
- It raises around the clock for as long as you take it. High IGF-1 over a long time is linked to higher cancer risk. Do not use it if you have had cancer.
Talk to a real doctor and check your bloodwork. We are not your doctor.
Where people get it.
Here are the ways people get it, from safest to riskiest.
- Brand. None. Merck dropped it, so there is no approved product.
- . A few pharmacies make capsules for about $90–$200 a month. Most real pharmacies do not carry it, since it is an odd fit for them.
- Research-only (). The main supply, about $30–$90 a month. Sold "for research only," often as a liquid. Purity is rarely tested.
- . Comes from overseas chemical sellers, not the usual sources. Quality unknown.
A common problem: liquids are sometimes mislabeled or mixed with other similar chemicals. Ask for a with a test so you know it is really MK-677 and not a look-alike.
Our honest take.
Here is the part gym chat leaves out: Merck ran this in older adults, saw a heart-failure signal, and walked away from its own drug. That silence is marketing, not safety.
What you are actually buying is a pill that mostly makes you hold water and feel hungry, in trade for rising blood sugar and a long-term cancer worry from that stays up around the clock. If you have a real, diagnosed growth-hormone problem, that is a doctor's job with a monitored, injected option, not this. For everyone else, skip it.
The studies behind this.
We read the research so you don't have to. Here's where the facts on this page come from.
- 01Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism. 1998;83(2):320-5. PMID: 9467534.
- 02Cardaci TD, et al. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology. 2022;107(12):1467-1476. PMID: 36303408.
- 03Cobani E, et al. Hepatotoxicity induced by MK-677. BMJ case reports. 2025;18(7). PMID: 40675653.
- 04Lee J, et al. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal. 2018;59(10):1174-1180. PMID: 30450851.
- 05Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews. 2018;6(1):45-53. PMID: 28400207.
- 06Bright GM, et al. A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial. Hormone research in paediatrics. 2022;95(1):76-81. PMID: 35354138.
- 07Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
- 08Kintz P, et al. Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue. Clinica chimica acta; international journal of clinical chemistry. 2026;578:120578. PMID: 40882886.
- 09Philip M, et al. Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control. Rapid communications in mass spectrometry : RCM. 2022;36(18):e9337. PMID: 35716382.
- 10Murphy MG, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1999;14(7):1182-8. PMID: 10404019.
- 11Chong S, et al. Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use. JCEM case reports. 2024;2(8):luae148. PMID: 39145153.
- 12Adunsky A, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics. 2011;53(2):183-9. PMID: 21067829.
- 13Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-8. PMID: 19015485.
- 14Murphy MG, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. The Journal of clinical endocrinology and metabolism. 2001;86(3):1116-25. PMID: 11238495.
- 15Viljanto M, et al. Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration. Drug testing and analysis. 2023;15(3):361-367. PMID: 36354265.
- 16Xu H, et al. Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency. Journal of medicinal chemistry. 2025;68(6):6766-6788. PMID: 40091212.
- 17Liu H, et al. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nature communications. 2021;12(1):6410. PMID: 34737341.
- 18Copinschi G, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86. PMID: 9349662.
- 19Codner E, et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clinical pharmacology and therapeutics. 2001;70(1):91-8. PMID: 11452249.
- 20Patchett AA, et al. Orally active growth hormone secretagogues. Pharmaceutical biotechnology. 1998;11:525-54. PMID: 9760695.
- 21Smith RG. Development of growth hormone secretagogues. Endocrine reviews. 2005;26(3):346-60. PMID: 15814848.
- 22Stawerska R. New directions in growth hormone treatment in children. Pediatric endocrinology, diabetes, and metabolism. 2025;31(4):143-154. PMID: 41693185.
- 23Hanauer SB. Sarcopenia and the elusive fountain of youth. Nature clinical practice. Gastroenterology & hepatology. 2009;6(1):1. PMID: 19127276.
- 24Philip M, et al. Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren. Rapid communications in mass spectrometry : RCM. 2021;35(23):e9201. PMID: 34542924.
- 25Tomillero A, et al. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. 2009;31(2):107-46. PMID: 19455266.
- 26Barrios MM, et al. SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON. Drug testing and analysis. 2025;17(10):2078-2085. PMID: 40551438.
- 27Chapman IM, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. The Journal of clinical endocrinology and metabolism. 1997;82(10):3455-63. PMID: 9329386.
- 28Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine reviews. 1997;18(5):621-45. PMID: 9331545.
- 29Svensson J, et al. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clinical endocrinology. 1999;50(4):451-6. PMID: 10468903.
- 30Svensson J, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1998;13(7):1158-66. PMID: 9661080.
- 31Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of clinical endocrinology and metabolism. 1998;83(2):362-9. PMID: 9467542.
- 32Yoon YS, et al. Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB reports. 2020;53(3):166-171. PMID: 31964466.
- 33Svensson J, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). The Journal of clinical endocrinology and metabolism. 1999;84(6):2028-33. PMID: 10372705.
- 34Svensson J, et al. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2003;13(1):1-7. PMID: 12550076.
- 35Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of clinical endocrinology and metabolism. 1996;81(12):4249-57. PMID: 8954023.
- 36Yau M, et al. Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited. Journal of the Endocrine Society. 2021;5(7):bvab096. PMID: 34141995.
- 37Hakim RM, et al. Anabolic interventions in ESRD: light at the end of the tunnel?. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009;54(2):201-4. PMID: 19556045.
- 38Smith RG. The aging process: where are the drug opportunities?. Current opinion in chemical biology. 2000;4(4):371-6. PMID: 10959763.
- 39Cutler C, et al. Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration. Drug testing and analysis. 2022;14(7):1273-1290. PMID: 35302297.
- 40Ghigo E, et al. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Annals of medicine. 1998;30(2):159-68. PMID: 9667794.
- 41Shimatsu A. [Ghrelin-related drugs: clinical perspectives]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:435-8. PMID: 15506422.
- 42Bayes M, et al. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. 2006;28(9):657-78. PMID: 17200730.
- 43Prahalada S, et al. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1999;31(2-3):133-7. PMID: 10226793.
- 44Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of internal medicine. 2008;149(9):677-9. PMID: 18981489.
- 45Abdul Ghafoor N, et al. Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines. Basic & clinical pharmacology & toxicology. 2025;136(1):e14111. PMID: 39668330.
- 46Svensson J, et al. Effects of growth hormone and its secretagogues on bone. Endocrine. 2001;14(1):63-6. PMID: 11322502.
- 47Komatsu Y, et al. [Ghrelin and bone metabolism]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:384-7. PMID: 15506410.
- 48Minamitake Y. [Structure-activity relationship of ghrelin]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:328-31. PMID: 15506395.
- 49Micic D, et al. Growth hormone secretagogues: the clinical future. Hormone research. 1999;51 Suppl 3:29-33. PMID: 10592441.
- 50Ghigo E, et al. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Hormone research. 1999;51 Suppl 3:9-15. PMID: 10592438.
- 51Lu Z, et al. Highly potent growth hormone secretagogues. Bioorganic & medicinal chemistry letters. 2007;17(13):3657-9. PMID: 17482461.
- 52Smith RG, et al. Growth hormone releasing substances: types and their receptors. Hormone research. 1999;51 Suppl 3:1-8. PMID: 10592437.
- 53Svensson JA, et al. Clinical and experimental effects of growth hormone secretagogues on various organ systems. Hormone research. 1999;51 Suppl 3:16-20. PMID: 10592439.
- 54Robinson IC. Hypothalamic targets for growth hormone secretagogues. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1997;423:88-91. PMID: 9401551.
- 55Svensson J. Growth hormone secretagogues as therapeutic agents. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999;9 Suppl A:107-9. PMID: 10429892.
- 56Muccioli G, et al. Growth hormone-releasing peptides and the cardiovascular system. Annales d'endocrinologie. 2000;61(1):27-31. PMID: 10790589.
- 57Smith RG, et al. Growth hormone secretagogue receptor family members and ligands. Endocrine. 2001;14(1):9-14. PMID: 11322507.
- 58Smith RG, et al. Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging. Annals of the New York Academy of Sciences. 2007;1119:147-64. PMID: 18056963.
- 59Piper T, et al. An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. Drug testing and analysis. 2021;13(5):916-928. PMID: 33283964.
- 60Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine. 2008;149(9):601-11. PMID: 18981485.
Learn about these too.
We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.
Want the rest of the peptide world, in plain English?
New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.